4.0 Article

Fenofibrate promotes neuroprotection in a model of rotenone-induced Parkinson's disease

Journal

BEHAVIOURAL PHARMACOLOGY
Volume 33, Issue 8, Pages 513-526

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FBP.0000000000000699

Keywords

fenofibrate; neuroinflammation; alpha-synuclein; Parkinson's disease; PPAR-alpha

Funding

  1. CNPq [454063/2014-8, 309567/2019-0]
  2. REUNI

Ask authors/readers for more resources

This study confirmed the neuroprotective effects of PPAR-alpha agonist fenofibrate in Parkinson's disease. The administration of fenofibrate reduced behavioral abnormalities, memory impairment, depletion of dopamine levels, dopaminergic neuronal death, and aggregation of alpha-synuclein in parkinsonian rats.
Parkinson's disease is a neurodegenerative disease, the etiology of which remains unknown, but some likely causes include oxidative stress, mitochondrial dysfunction and neuroinflammation. Peroxisome-proliferator-activated receptor (PPAR) agonists have been studied in animal models of Parkinson's disease and have shown neuroprotective effects. In this study, we aimed to (1) confirm the neuroprotective effects of PPAR-alpha agonist fenofibrate. To this end, male rats received fenofibrate (100 mg/kg) orally for 15 days, 5 days before the intraperitoneal injections of rotenone (2.5 mg/kg for 10 days). After finishing the treatment with rotenone and fenofibrate, animals were subjected to the open field, the forced swim test and the two-way active avoidance task. Subsequently, rats were euthanized for measurement of dopamine and metabolites levels in the striatum and quantification of tyrosine hydroxylase-immunoreactive neurons in the substantia nigra pars compacta (SNpc). In addition, we aimed to (2) evaluate the neuroprotective effects of fenofibrate on the accumulation of alpha-synuclein aggregates. Here, rats were treated for 5 days with fenofibrate continuing for over 28 days with rotenone. Then, animals were perfused for immunohistochemistry analysis of alpha-synuclein. The results showed that fenofibrate reduced depressive-like behavior and memory impairment induced by rotenone. Moreover, fenofibrate diminished the depletion of striatal dopamine and protected against dopaminergic neuronal death in the SNpc. Likewise, the administration of fenofibrate attenuated the aggregation of alpha-synuclein in the SNpc and striatum in the rotenone-lesioned rats. Our study confirmed that fenofibrate exerted neuroprotective effects because parkinsonian rats exhibited reduced behavioral, neurochemical and immunohistochemical changes, and importantly, a lower number of alpha-synuclein aggregates. Copyright (C) 2022 Wolters Kluwer Health, Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available